Pricing

Ovid Therapeutics Inc (OVID)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeremy M. Levin
Employees:
60
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001
212-776-4381
Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available